

MANUAL OF PATENT EXAMINING PROCEDURE

PTO/SB/08 (2-92)

Sheet 1 of 1									
Form PTO-1449			Docket Number (Optional)		Application Number				
				3153.00451 10/673,008					
INFORMATION DISCLOSURE CITATION				Applicant Deng, et al.					
	IN AN APPLICA								
İ				Filing Date 09/26/2003		Group Art Unit			
(U.	se several sheets if					1636			
		U.S	<u>. PATEN</u>	T DOCUME	NTS	•	_		
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
A	6,713,286	03-2004	Deng, et al.		435	91.33			
N	6,764,676	07-2004	Deng, et al.		424	93.21			
oz	2004/0096460	05-2004	Deng, et al.		424	199.1			
		FOREI	GN PAT	ENT DOCU	MENTS				
						TRANSLATION			
	DOCKET NUMBER	DATE	COUNTRY		CLASS	SUBCLASS	YES	_ NO	
	OTHER DOC	UMENTS	(Includir	ng Author, Title	, Date Pertin	ent Pages, E	tc.)	•	
EXAMINER				DATE CONSIDERED					
David Jugo				1/4/06					
	EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.								

PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE



MANUAL OF PATENT EXAMINING PROCEDURE PTO/SB/08 (2-92)

						_l_of_1		
Form PTO-1449			Docket Number (Optio 3153.00451	Application Number 10/673,008				
INFORMATION DISCLOSURE CITATION IN AN APPLICATION			Applicant Deng, et al.					
			Filing Date	Group Art U	Group Art Unit			
(Use several sheets if necessary)			09/26/2003		1636			
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME		CLASS	SUBCLASS		DATE OPRIATE
- PC	5,177,014	01-1993	O'Connor et al.		435	188		
. 01	5,833,883	11-1998	Wardley et al.		424	208.1		
. 81	6,004,799	12-1999	Luciw et al.		435	236		
· 61	6,300,118 B1	10-2001	Chavez et al.		435	252.3		
. 0	6,348,196 B1	02-2002	Audonnet et al.		424	202.1		
02	6,383,765	05-2002	Andersen et al.		435	7.92		
	FOREIGN PATENT DOCUMENTS							
	DOCKET NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	YES	NO
· ol	WO 9530019	11-1995	PCT					
. 81	WO 9640268 12-1996 PCT							
. 07	/// WO 9732983 09-1997 PCT		PCT		•			
. 01	WO 9803660 01		PCT		,			
. 01	· 67 WO 9821354 05-199		PCT		,			
• 67	<i>Ø</i> WO 9840493 09-199		PCT					
• 01	WO 9840957 09-1998 PCT		PCT		,			
· 91	· 97 0997529A2 08-19		EP		,			_
· 8	2751223A1 07-1996 FR		FR					
	OTHER DOC		(Includin	ng Author, Title, Da	te Pertine	ent Pages, Et	c.)	
n	Andresson et al., Nucleotide sequence and biological properties of a pathogenic proviral molecular clone of neurovirulent visna virus. Virol. 1993, Vol. 193, pages 89-105. See entire document.							
· 197	Baldinotti, et al.,	al., J. Virol., Vol. 68:4572-5479 (1994)						
· (91	Baumberger, et al., AIDS, 7:S59-S64 (1993) Bishop, et al., Vaccine, Vol. 14:1243-1250 (1996)							
. 81	Boyer, et al., Protection of Chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination, Nature Medicine, Vol 3, Numbers 5, Pages 526-532, May 1997.							
· OZ						ttenuated 5, pages		

	845-850. See entire document.					
·or	Cuisinier, et al., Vaccine. Vol. 15:1085-1094 (1997)					
. Ge	Cuisinier, et al., Attempt to modify the immune response developed against FIV gp120 protein by preliminary FIV DNA injection, Vaccine 17, p 415-425, Elsevier Science Ltd. (1999)					
• 61	Diehl, et al., J. Virol., Vol. 69:2328-2332 (1995)					
· Se	Diehl, et al., J. Virol., Vol. 70:2503-2507 (1996)					
97	Elyar, et al., Vaccine, Vol. 15:1537-1444 (1997)					
•	Franchini et al. Highly attenuated HIV type 2 recombinational poxviruses, but not HIV-2 recombinant Salmonella vaccines, induce long-lasting protection in rhesus macques. AIDS Res. Human Retro. 1995, Vol. 11, No. 8, Pages 909-920. See entire document.					
· p	Gonda et al. Bovine immunodeficiency virus: molecular biology and virus-host interactions. Virus Res. 1994, Vol. 32, pages 155-181. See entire document.					
01	Hoesie, et al., DNA Vaccination Affords Significant Protection against Feline Immunodeficiency Virus Infection without inducing Detectable Antiviral Antibodies, Journal of Virology, Vo. 72, No. 9, p. 7310-7319, Sept. 1998					
67	Okuda et al. Induction of potent humoral and cell-mediated immune response following direct injection of DNA encoding the HIV type 1 env and rev gene products. AIDS Res. Human Retro. 1995, Vol. 11, No. 8, pages 933-943. See entire document.					
01	Olmsted, et al., Molecular cloning of feline immunodeficiency virus. Proc. Natl. Acad. Sci. USA. April 1989, Vol. 86, pages 2448-2452. See entire document.					
n	Pincus et al. Poxvirus-based vectors as vaccine candidates. Biologicals. 1995, Vol. 23, pages 159-164. See entire document.					
· A	Saltarelli et al. Nucleotide sequence and transcriptional analysis of molecular clones of CAEV which generate infectious virus. Virol. 1990, Vol. 179, pages 347-364. See entire document.					
· OT	Von Schwedler, et al., Retroviral-Mediated Expression of FIV Envelope/Rev Induces CD8+ CTL Response in Mice, Intervirology 1997; 40:271-276.					
91	Wardley et al. The use of feline herpesvirus and baculovirus as vaccine vectors for the gag and env genes of feline leukaemia virus. J. Gen. Virol. 1992, Vol. 73, pages 1811-1818. See entire document.					
R	Whetter, et al., Equine infectious anemia virus derived from a molecular clone persistently infects horses. J. Virol. December 1990, Vol. 64, No. 12, pages 5750-5756. See entire document.					
EXAMINER	DATE CONSIDERED					
<u> </u>	David Juso 1/4/06					

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

^{*}Copies of all of the references cited herein were previously provided and considered by the Examiner during the prosecution of the parent application, now U.S. Patent No. 6,667,298.